US7001736B1 - Pharmacogenetic methods for use in the treatment of nervous system diseases - Google Patents
Pharmacogenetic methods for use in the treatment of nervous system diseases Download PDFInfo
- Publication number
- US7001736B1 US7001736B1 US09/500,162 US50016200A US7001736B1 US 7001736 B1 US7001736 B1 US 7001736B1 US 50016200 A US50016200 A US 50016200A US 7001736 B1 US7001736 B1 US 7001736B1
- Authority
- US
- United States
- Prior art keywords
- apoe4
- patient
- apoe
- patients
- allele
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Definitions
- the invention relates to the treatment of neurological disease.
- Apolipoprotein E functions as a ligand in the process of receptor mediated internalization of lipid-rich lipoproteins. ApoE is probably also involved in reverse lipid transport.
- apoE plays a central role in the mobilization and redistribution of cholesterol and phospholipid during membrane remodeling associated with synaptic plasticity (Poirier J. et al., 1991, Mol. Brain. Res., 9:191–195; Poirier J. et al., 1991, Mol. Brain. Res., 11:97–106; Poirier J. et al., 1993, Neuroscience, 55:81–90).
- apoE in the brain is further underscored by the absence of other key plasma apolipoproteins such as apoA1 and apoB in the brain (Roheim P. S. et al., 1979, Proc. Natl. Acad. Sci., 76:4646–4649).
- Neurological diseases provide a unique series of complications for the clinicians, patients, and care givers; the diseases often progress rapidly and disrupt a vast number of major life functions. The progressive nature of these diseases makes the passage of time a crucial issue in the treatment process.
- Treatment choices in the neurological disease context are complicated by the fact that it often takes a significant period of treatment to determine whether or not a drug is having a therapeutic effect. Accordingly, treatment with the most effective drug or drugs is often delayed while the disease continues to progress.
- a method which would allow one to predict which patients will respond to specific therapeutics and dosages would provide physical and psychological benefits. As healthcare becomes increasingly inaccessible, the ability to allocate healthcare resources effectively also becomes increasingly important.
- the pharmacogenetic methods of the invention allow the clinician to avoid serially administering therapeutics until a therapeutic which works is discovered through trial and error; with pharmacogenetics an appropriate therapeutic can be administered on the first round of therapy.
- This method will provide more rapid treatment with the appropriate drug and drug dose. Even where drug therapy is inappropriate, the method will provide patients with a prognosis and will allow the patient the option of avoiding what may be needless drug side-effects.
- the pharmacogenetic method has an additional advantage when utilized in the field of drug testing.
- the method allows the patient being considered for enrollment in a drug trial to be classified as likely or unlikely to benefit from a cholinomimetic therapy. If the patient is likely to respond to a cholinomimetic, and the drug being tested is not a cholinomimetic, then the patient may be physically unsuitable for the trial or it may be ethically inappropriate. Conversely, patients likely to respond to cholinomimetics will provide more statistically useful data on novel cholinomimetic therapeutics. Patients unlikely to respond to cholinomimetic drugs are particularly good candidates for non-cholinomimetic therapies from both a physical and ethical perspective.
- the invention provides a method of creating a prognosis protocol for a patient diagnosed with a neurological disease or Alzheimer's disease (AD).
- the method includes: a) identifying a patient already diagnosed with said disease; b) determining the apoE allele load of said patient; and c) converting the data obtained from step b into a prognosis protocol.
- the prognosis protocol may include a prediction of drug efficacy, a prediction of patient outcome, or both.
- the methods may further include the steps of obtaining a patient profile, which may, preferably, include the patient's sex and/or genotype (e.g., presenilin genotype or apolipoprotein E genotype).
- the invention provides a method for identifying non-AD patients for participation in clinical trail of a drug for the treatment of a non-AD neurological disease or AD.
- the methods include: a) identifying a patient already diagnosed with said non-AD neurological disease or AD; b) determining the apoE allele load of said patient; and c) converting the data obtained from step b into a prognosis protocol.
- the prognosis protocol provides an indication of whether or not said patient is a candidate for a cholinomimetic drug trial or non-cholinomimetic drug trial. Patients who have one or more apoE4 alleles are poor candidates for the trial of a cholinomimetic drug trials.
- Cholinomimetic drugs may be selected from the group consisting of inhibitors of acetylcholine degradation, inducers of acetylcholine synthesis, acetycholine agonists or mimics, and muscarinic M2-receptor antagonists. It should be noted that the therapies suggested by the pharmacogenetic method may be used alone, or in combination with other known therapies that are not otherwise contraindicated for the patient.
- “Cognitive enhancers” means drugs which enhance a) memory performance, whether it is verbal memory, spatial memory, or factual memory and b) learning capacity.
- “Cholinomimetic therapies” means drugs that mimic the function of acetylcholine or enhance the activity of remaining acetylcholine synthesizing cells. These drugs include, but are not limited to, inhibitors of acetylcholine degradation (acetylcholine esterase inhibitors like tacrine), drugs that mimic acetylcholine structure and function (agonist: muscarinic M1-receptor agonist is a typical example), drugs that block acetylcholine uptake by neurons and drugs that interact pre-synaptic receptors to induce acetylcholine release from cholinergic neurons.
- inhibitors of acetylcholine degradation acetylcholine esterase inhibitors like tacrine
- drugs that mimic acetylcholine structure and function agonist: muscarinic M1-receptor agonist is a typical example
- ApoE probes means nucleic acid probes or ApoE allele specific antibodies that selectively recognize the apoE2, apoE3 or apoE4 alleles or proteins, respectively.
- Non-AD Neurological disease means any disease other than Alzheimer's disease, which involves the neuronal cells of the nervous system.
- prion diseases e.g, Creutzfeldt-Jakob disease
- pathologies of the developing brain e.g., congenital defects in amino acid metabolism, such as arginosuccinic aciduria, cystathionuria, histidinaemia, homocystinuria, hyperammonaemia, phenylketonuria, and tyrosinaemia, and fragile X syndrome
- pathologies of the mature brain e.g., neurofibromatosis, Huntington's disease, depression, amyotrophic lateral sclerosis, multiple sclerosis, and stroke
- conditions that affect the elderly e.g.
- AD Alzheimer's Disease
- Allele load means the relative ratio of apoE2, 3, and 4 alleles in the patient's chromosomal DNA. The allele load may be determined by comparing the relative numbers of the patient's already known apoE allele types.
- Prognosis protocol means a therapy plan provided to the clinician or patient using the pharmacogenetic method.
- the prognosis protocol includes an indication of whether or not the patient is likely to respond positively to a cholinomimetic therapeutic.
- the protocol also includes an indication of the drug dose to which the patient is most likely to respond.
- the pharmacogenetic method is a method whereby genetic and diagnostic data, including the patient's neurological diagnosis and the patient's apoE genotype are processed to provide therapeutic options and prognoses.
- FIGS. 4A and 4B are graphs illustrating E4 allele copy number and choline acetyltransferase activity in Alzheimer's disease.
- FIGS. 6A–6J are graphs illustrating the effect of apo E4 allele copy number on a) choline acetyltransferase activity, b) nicotinic receptor density, c) total muscarinic receptor density, d) muscarinic M1 (post-synaptic) and e) muscarinic M2 receptor density in post-mortem non-AD and AD brains in the hippocampal formation and temporal cortex.
- FIG. 7 is a graph illustrating the individual neuropathological and morphological characteristics associated to the cholinergic system in the brain of the various Alzheimer's disease and control cases investigated.
- FIGS. 9A and 9B are graphs of the ADAS-COG Scores with tacrine and xanomeline, respectively, from day 0–week 30.
- FIG. 10 is a graph of the effect of the presence of the apoE4 allele on the ADAS-COG Scores in FIGS. 9A and 9B .
- FIG. 11 is a graph of the brain apoE levels in AD subjects as a function of the apoE allele load.
- Losses of cholinergic neurons and/or ChAT activity are well known hallmarks of AD (Perry E. K. et al, 1977, J. Neurol. Sci., 34:247 265; Davies P. et al, 1976, Lancet, 2:1403).
- reduction in ChAT activity in the hippocampus and temporal cortex of AD cases is inversely proportional to the apoE4 allele copy number (i.e. where the apoE4 allele copy number is increased the ChAT activity is decreased).
- FIGS. 1 and 2 illustrate Western and Northern blot analyzes of apoE levels in the hippocampus of non-AD and AD patients as a function of their respective genotype.
- Frozen hippocampi from post-mortem patients were obtained from the Douglas Hospital Brain Bank in Quebec. Age and sex were matched and post-mortem delays were similar from the two groups ( ⁇ 14 hrs). Post-mortem delays up until 24 hours have little impact on apoE stability (Lehtimaki T., 1991, Clin. Chim. Acta, 203:177–182) and it can be stored at ⁇ 80° C. for several months without noticeable trace of degradation. Hippocampal total RNA was extracted and quantified by oligo(dT) hybridization as described previously (Poirier J. et al., 1991, Mol. Brain. Res., 11:97–106).
- Hybridization protocol of the full length apoE cRNA probe used in these experiment was described before (Poirier J. et al., 1991, Mol. Brain. Res., 9:191–195). High molecular weight DNA was isolated from frozen cerebellum or temporal cortex as adapted from Goelz et al. (Goelz S. E. et al., 1986, Biochem. Biophys. Res. Comm., 130:118–126).
- ApoE genotype was determined by allele-specific extension of purified brain DNA using a modification of the method of Main et al. (Main R. F. et al., 1991, J. Lipid. Res., 32:183–187).
- the primers labeled D, E, F, G, and H were synthesized for us by Genosys Biotech (The Woodland, Tex.); the primer sequences are given in Main et al. (Main R. F. et al., 1991, J. Lipid. Res., 32:183–187).
- Reactions were carried out in a volume of 50 uL containing 1 ug of DNA; deoxyadenosine triphosphate, deoxycytidine triphosphate, deoxythymidine triphosphate and deoxy guanosine triphosphate, each 0.2 mmol/L; 10% dimethyl sulfoxide; 12.5 pmol of either primer D, E, F, G; 25 pmol of primer H; and 10 uL of 10 PCR reaction buffer (Vector Biosystem, Toronto, ONT.).
- the DNA in the reaction mixture was first denatured for 10 min. at 96° C. and then cooled to 4° C.
- One unit of Taq polymerase (Vector Biosystem, Toronto, ONT.) was then added to each sample.
- FIG. 10 illustrates levels of apoE measured in the brain of AD subjects with different genotypes as well as in control subjects with apoE3/2 and apoE3/3 genotypes.
- apoE3/2 and apoE3/3 genotypes Of the ⁇ 90 neuropathological elderly control subjects that I have examined so far (using standard criteria), none of those fitting the AD criteria were found to carry the E4 allele. A significant reduction in apoE tissue concentration was measured in apoE4 carriers versus non-E4 subjects.
- AD pathology is much more severe (cell loss, deafferentation and increased GFAP expression, etc.) in apoE4 AD carriers than it is in the apoE4-negative AD subjects. Yet, apoE levels, which should be increased in response to damage and cell loss, are in fact decreased in those same apoE4 individuals.
- Betatubulin was used as a non-changer transcript to adjust for RNA loading in the gels.
- GFAP mRNA prevalence a well known marker of local tissue damage is markedly increased in apoE4 carriers when compared to apoE3/3 AD subjects: supporting the notion of more severe damages in the brain of apoE4 carriers.
- the LDL receptor and HMG-CoA reductase mRNA prevalence were found to be increased in AD subjects carrying the apoE4 allele when compared to non-E4 carriers.
- Genotype was determined as described for FIG. 1 .
- Senile plaque and tangle density measures were performed as described before (Aubert I. et al., 1992, J. Neurochem., 58:529–541).
- Paraffin embedded hippocampal tissue from 59 autopsied AD patients was obtained from the Douglas Hospital Brain Bank and stained with hematoxylin and eosin, modified Bielchowsky, and alkaline Congo red.
- Quantitative morphometric evaluations of neurofibrillary tangles and senile plaques were done as follows. A micrometric scale was used for calibration. Readings were done with a 10 ⁇ objective for plaques and 25 ⁇ objective for tangles. Diffuse plaques were excluded from these measurements.
- IPD Idiopathic Parkinson's disease
- FIGS. 4 and 6 illustrate the effect of the presence of apoE4 isoform on hippocampal and temporal cortex ChAT activity.
- CHAT activity values are 9.44 ⁇ 0.93 (control apo E3/3, no apoE4 allele), 6.09 ⁇ 0.36 (AD apoE3/3, no apoE4 allele), 3.21 ⁇ 0.31 (AD apoE4/3) and 2.94 ⁇ 1.52 (AD apoE4/4) nmol Ach/mg protein/hr, respectively.
- the apoE4 allele copy number-rated reduction in ChAT activity and nicotinic receptors may be caused by at least one of two distinct phenomena.
- phospholipids such as PC and PE which can serve as precursors to choline in the synthesis of Ach could be transported into neurons via the classical apoE-LDL receptor pathway.
- An isoform-dependent impaired regulation of the transport of phospholipids in the brain of apoE4 carriers could explain the reduced levels of PC, PE and choline reported in AD; this then leading to decreased Ach synthetic capacities.
- the reduction in neuronal ChAT activities and choline levels could be secondary to losses of cholinergic neurons.
- NBM nucleus basalis of Meynert
- DBB diagonal band of Broca
- High molecular weight DNA for genotype analysis was isolated from frozen cerebellum or temporal cortex as adapted from (Nalbantoglu J. et al., 1994, Predictive value of apolipoprotein E4 mutation in Alzheimer's Disease, Ann. Neurol. 36:889–895).
- ApoE genotype was determined by allele-specific extension of purified brain DNA using (Nalbantoglu J. et al., 1994, Predictive value of apolipoprotein E4 mutation in Alzheimer's Disease, Ann. Neurol. 36:889–895).
- the primers labeled D, E, F, G, and H were synthesized for us by Genosys Biotech (The Woodland, Tex.); primer sequences are given in Main et al.
- reaction products were visualized by electrophoresis of 10 uL of the reaction mixture in a 1% agarose gel containing TPE buffer (0.08 mol/L Tris-phosphate, 0.002 mol/L EDTA, Sigma, St-Louis, USA) and ethidium bromide (0.15 ug/mL) for 1 hr at 67v.
- TPE buffer 0.08 mol/L Tris-phosphate, 0.002 mol/L EDTA, Sigma, St-Louis, USA
- ethidium bromide 0.15 ug/mL
- Neuropathological Analyses Neurofibrillary tangle and senile plaque indices were determined as described in detail elsewhere (Aubert I. et al., 1992, J. Neuro chem., 58:529–541; Etienne P. et al, 1986, Neuro science, 19:1279 1291). Fifteen micron paraffin embedded hippocampal sections were stained with either hematoxylin and eosin, modified Bielchowsky stain, and alkaline Congo red to visualize neurofibrillary tangles and senile plaques.
- Quantitative morphometric evaluation of neurofibrillary tangles and senile plaques were determined: using a micrometric scale for calibration readings were done with a 10 ⁇ objective for senile plaques and a 25 ⁇ objective for neurofibrillary tangles. Diffuse plaques were excluded from all measurements. Screening of alkaline Congo red stains under polarized light was used to control for the reliability of tangle staining and, to a lesser extent, of the senile plaques' affinity for the modified Bielchowsky preparation. These criteria are consistent with those used in the classification of Khachaturian (Aubert I. et al., 1992, J. Neurochem., 58:529–541).
- [3H]QNB (45.7 Ci/mmol), [3H]PZ (87.0 Ci/mmol), [3h]AF-DX 116 (49.3, 57.0, or 70.0 Ci/mmol), [3H]MCC (84.5 Ci/mmol), and [4C]acetyl-CoA (48.8 mCi/mmol) are purchased from New England Nuclear (Boston, Mass., U.S.A.). Nicotine (free base), atropine sulfate, choline chloride, and eserine hemisulfate salts are bought from Sigma Chemical Co. (St. Louis, Mo., U.S.A.). ACH chloride was supplied by Hoffmann-LaRoche (Basel, Switzerland).
- Unlabelled acetyl-CoA are purchased from Boehringer Mannheim (Mannheim, F.R.G.). TetraphenylboronTM (sodium salt) and 3-heptanone are purchased from Aldrich Chemical Co. (Milwaukee, Wis., U.S.A.). Ethyl acetate was bought from American Chemicals Co. (Montreal, Quebec, Canada). Bovine serum albumin (98% fatty acid free) and Ecolite scintillation cocktail are purchased from ICN Bio chemicals (Irvine, Calif., U.S.A.). TritonTM X-100 (100%) scintillation grade was from Amersham (Arlington, Ill., U.S.A.). All other chemicals were from Fisher Scientific (Montreal, Quebec, Canada).
- Human brain tissues are obtained at autopsy from individuals clinically diagnosed as having AD, PD, or PD/AD and from neurological normal age-matched controls. Tissues are provided by the Brain Bank of the Douglas Hospital Research Center (Y. Robitaille, neuropathologist). Histopathological criteria have been described earlier. Hemispheres to be used for bio chemical assays are sectioned into thick (10 mm) coronal slices quickly and deeply frozen in 2-methylbutane at ⁇ 40° C. before storage at ⁇ 80°.
- brain slices are slowly thawed on a cold plate, and the following structures are dissected as follows: frontal (Brodmann areas 9 and 10) and temporal (Brodmann areas 20, 21, 22, and 38) cortices, hippocampus and cerebellum (use as a low pathology brain area).
- Binding parameters were derived from the saturation experiments analyzed by the computerized method LIGANDTM (Aubert I. et al., 1992, J. Neurochem., 58:529–541). Statistical significance of differences between control and AD (0, 1, 2 copies of E4 alleles) brain was evaluated using Student's unpaired t test, with values of p ⁇ 0.05 being considered significant.
- Tissues from various brain regions were homogenized and incubated for 15 min. in buffer containing [14C]acetyl-CoA as previously described in details (Aubert I. et al., 1992, J. Neurochem., 58:529–541) to determine ChAT activity.
- cholinergic marker enzymes such as ChAT
- FIG. 6 the apoE4 allele copy number is inversely correlated with ChAT activity in the hippocampus and temporal cortex of age-matched control and AD subjects.
- each bar refers to mean value+S.E.M.
- Significant differences between groups are indicated by the number of stars: *: p ⁇ 0.05, **: p ⁇ 0.01, *** ⁇ 0.001. Striking reductions in ChAT activity were seen in apoE4 carriers.
- ChAT values are represented in FIG. 1 in the hippocampus (23 ADs and 30 controls) and temporal cortex (30 ADs and 12 controls) of AD subjects with different doses of apoE4 allele.
- Acetylcholinesterase positive neuron density in the sub-cortical areas projecting to the temporal cortex and hippocampal structures are represented in FIG. 7 .
- Neuronal cell density in the Ch2, Ch4a and Ch4i are expressed as percent of control values.
- Nucleolar volume is expressed in um2.
- Plaque density is expressed as number per mm3 in the hippocampus of the same patients. Portion of these results were published by Etienne and Colleagues (1986, Neuroscience, 19: 1279–1291). The genotype of the original patients was unknown and could not be done then. Since then, we reanalyzed the data in subjects for which genotype could be determined.
- Three AD subjects are apoE4 negative whereas four AD subjects are apoE4-positive.
- Bound [3H]QNB is separated from free ligand by rapid filtration under reduced pressure through Schleicher & Schuell No. 32 glass filters, presoaked in 0.1% polyethylenimine solution, using a Brandel Cell Harvester apparatus (Brandel, Gaithersburg, Md., U.S.A.). Filters are then rapidly washed with ice-cold buffer, three times with 4.5 ml each, before being dried. The radioactivity of the filters is determined by liquid scintillation counting using a Beckman model LS7000 scintillation counter at 48% efficiency. Nonspecific binding, defined in the presence of 1 ⁇ M atropine sulfate, represents usually ⁇ 15% of total binding.
- Brain tissues are processed as described above for [3H]QNB. Aliquots of final homogenates are incubated in Krebs buffer with various concentrations of [3H]AF-DX 116 (0.1–20 nM) for 60 min. at 4° C. Assays are terminated and radioactivity is determined as described above for [3H]QNB binding. Nonspecific binding, defined in the presence of 1 ⁇ M atropine sulfate, represents usually ⁇ 40% of total binding at ligand concentrations approximating Kd values.
- Muscarinic binding sites are not altered in the hippocampus of AD versus control subjects.
- the apoE genotype has no significant impact on the activity of these receptors. Muscarinic M1 and M2 receptor sites are not alters in AD versus control subjects in the temporal cortex whereas the so-called total (QNB) muscarinic binding sites are slightly reduced in AD versus control subjects (no genotype effect on this receptor group).
- QNB total muscarinic binding sites
- Brain tissues are processed as described above for [3H]QNB with the exception that samples were homogenized in 50 mM Tris-HCl buffer. Aliquots of final homogenates were incubated in 50 mM Tris-HCl buffer with various concentrations of [3H]MCC (0.1–20 nM) for 60 min. at 4° C. Assays are terminated and radioactivity is determined as described above for [3H]QNB binding. Nonspecific binding, defined in the presence of 10 ⁇ M nicotine, represents usually ⁇ 50% of total binding at ligand concentrations approximating Kd values.
- Nicotinic Receptor Binding Sites are significantly reduced in apoE4 AD subjects where AD subjects not carrying apoE4 are not different from controls subjects. This is valid for both the hippocampal and the temporal areas in AD.
- apoE genotype may directly influence the synaptic plasticity of the cholinergic system in response to neuronal cell loss.
- apoE4 compromises lipid homeostasis and consequently impairs membrane remodeling.
- the fact the cholinergic system is the only neurotransmitter system of the brain that requires lipid (not amino acids) to synthesize its neurotransmitter (the acetylcholine) further highlights the selective vulnerability of this system in a situation of poor lipid delivery and/or availability.
- Acetylcholinesterase-Inhibitor Treatment in Humans with AD Clinical Effect of apoE Genotype.
- the ADAS-cog is an objective test that evaluates memory, attention, reasoning, orientation and praxis: a decrease score over time (or a positive difference) indicates improvement (Rosen W. G. et al, 1984, Am. J. Psychiatr., 141:1356 1364).
- the AD total includes the cognitive and non-cognitive portion of the ADAS.
- FIG. 8 illustrates the drug responsiveness (ADAD-cog and AD total) of AD subjects a function of apoE4 allele. Each bar represents an individual subjects. Positive delta values (difference in AD score at the end minus AD score prior to drug treatment) indicate improvement in cognitive performance (ADcog) and in global performances (ADAS-total). Negative values represent patients who deteriorated over time and drug treatment. All the subjects are AD subjects, all were treated with the same drug, at the same level, for the same duration. The only critical factor that differentiates them is the presence or absence of the apoE4 allele.
- Result clearly indicates that more than 85% of the apoE4 negative subjects show improvement with tacrine administration (AD total) where 60% of the apoE4 positive subjects are worse following drug treatment. In other words, 4 out 5 subjects that do not respond to tacrine are apoE4 positive.
- the ADAS-cog scale shows similar response profile in apoE4 carriers and non-carriers.
- the 30-week study was randomized, double-blind, placebo-controlled, parallel-group clinical trial conducted at 33 centers in the USA (see Knapp, M. J. et al. JAMA 271: 985–991 (1995) for complete methodology).
- Patients randomized to tacrine treatment received an initial dose of 40 mg/day (10 mg QID) and were force-titrated at 6-week intervals in increments of 40 mg to maximum dose levels of 80, 120, and 160 mg/day for Groups II, III, and IV, respectively.
- Group I received placebo for the entire 30 weeks.
- the protocol was approved by Institutional Review Boards for each study center and followed guidelines of the Declaration of Helsinki and Good Clinical Practices.
- NINCDS National Institute of Neurological and Communicative Disorders and Stroke
- Patients were otherwise healthy and did not have significant extra pyramidal, cerebrovascular, cardiac, or hepatic disease; insulin-dependent diabetes mellitus; or chronic renal insufficiency.
- Disease severity at the time of study entry was defined mild to moderate based on Mini-Mental State Examination. (MMSE) scores between 10 and 26 inclusive.
- MMSE Mini-Mental State Examination.
- Written informed consent was obtained from care givers and patients or their legal representatives. Medications with known central nervous system effects were prohibited during double-blind treatment. Once patients completed or terminated from the double-blind phase of the study there were no restrictions on concurrent medications. Patients who stopped tacrine treatment could take other investigational drugs.
- the ADAS-Cog is an objective test that evaluates memory, language, and praxis and is a sensitive measure of patient performance (maximum severity score of 7). A decrease in score indicates improvement.
- the CIBIC is a global evaluation of change and is intended to determine whether the effects of an antidementia drug are large enough for detection by an experienced, skilled clinical observer during a comprehensive clinical interview with the patient.
- input from the patient and family members are accepted in addition to a review of the patient's test performance.
- clinician's assessment is based solely on an interview with the patient, without regard to test performance or family observations.
- the patient is rated on a 7-point scale: 1, very much better; 4, no change; and 7, very much worse.
- the FCCA is also a 7-point scale. Similar to the CIBIC, a review of psychometric test scores is excluded, but input from family members is allowed. The FCCA was conducted after the CIBIC and only when the patient completed or withdrew from the study.
- Each site provided data on the dates of death and/or NHP if either occurred during the 2-year follow-up period.
- CIBIC and FCCA scores were analyzed using Cochran-Mantel-Haenszel (CMH) methods on modified ridit scores, stratifying by site in the unadjusted analyses and stratifying by site and Apo E4 status in the adjusted analyses.
- CSH Cochran-Mantel-Haenszel
- Nonparametric p-values for CIBIC and FCCA were used to determine if tacrine treatment effects were statistically significant.
- ADAS-Cog scores at Week 30 were estimated for: (1) placebo patients with an E4 allele, (2) placebo patients without an E4 allele, (3) TacrineTM 160 mg/day patients with an E4 allele, and (4) TacrineTM 160 mg/day patients without an E4 allele using ANCOVA that adjusted for site and baseline score.
- Week 30 CIBIC and FCCA scores were estimated using ANOVA adjusted for study site effects.
- PROC LOGISTIC 21 adjusted for baseline Instrumental Activities of Daily Living (IADL), other investigational anti-dementia agents, age, gender and presence or absence of the E4 allele was used for performing logistic regressions 22 to analyze NHP and mortality data.
- Patients were grouped according to the last daily dose of tacrine received (0–40 mg/day, >40–80 mg/day, >80–120 mg/day, and >120–160 mg/day).
- Estimated treatment differences between the 0 to 40 mg/day group and other 3 groups were computed using odds ratios.
- a similar model included additional indicator variables for treatment x Apo E4 interactions.
- NHP and mortality data were also analyzed without adjusting for the presence or absence of the E4 allele for all randomized patients and for patients with and without the E4 allele.
- Table I shows, correlation of the drug dosage, patient sex, and apoE allele load a critical element of the appropriate treatment protocol. For example, men having no E4 allele do best with either low or high doses, men with a single E4 allele require a high dose for maximum effect, and men having two E4 alleles do not respond to tacrine. By contrast, women having no E4 allele do best with a mid-level tacrine dose, while those with one E4 allele do equally well at any dose. Like men, those women having two E4 alleles do not respond to tacrine.
- our method allows one to provide the clinician and the patient with a report having the lowest dose which indicates the highest effectivity for a given patient. This finding allows for correlation of the maximum level of therapeutic drug responsiveness with the minimum level of side effects.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Electrotherapy Devices (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
TABLE 1 |
mRNA Prevalence in the Hippocampus of AD |
Apo E3/3 | Apo E4/3 | Apo E4/4 |
Genes | % OF CONTROLS | ||
GFAP | 110 | 365* | 345* | ||
LDL | 86.5 | 173* | 170* | ||
HMG-CoA | 87 | 191* | 152 | ||
N = 6 | N = 7 | N = 3 | |||
*:p < 0.05 |
TABLE 1 |
BEST RESPONDERS AND Apo E |
ADAS-COG IMPROVE |
E4/4 | E4/X | EX/ | ||
MEN |
PLACEBO |
0 | 24 | 14 | ||
Tacrine low | 0 | 14 | 33 | |
Tacrine mid | 0 | 34 | 0 | |
Tacrine high | — | 69 | 29 |
|
PLACEBO |
0 | 26 | 14 | ||
Tacrine low | 0 | 20 | — | |
Tacrine mid | 0 | 24 | 67 | |
Tacrine high | — | 20 | 43 | |
% of subjects with an improvement of the ADAS-COG score by at least 5 points on the scale |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/500,162 US7001736B1 (en) | 1995-04-26 | 2000-02-08 | Pharmacogenetic methods for use in the treatment of nervous system diseases |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CA1995/000240 WO1995029257A2 (en) | 1994-04-27 | 1995-04-26 | Apolipoprotein e polymorphism and treatment of alzheimer's disease |
US72763796A | 1996-10-16 | 1996-10-16 | |
US08/766,975 US6022683A (en) | 1996-12-16 | 1996-12-16 | Methods for assessing the prognosis of a patient with a neurodegenerative disease |
US09/500,162 US7001736B1 (en) | 1995-04-26 | 2000-02-08 | Pharmacogenetic methods for use in the treatment of nervous system diseases |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/766,975 Continuation US6022683A (en) | 1995-04-26 | 1996-12-16 | Methods for assessing the prognosis of a patient with a neurodegenerative disease |
Publications (1)
Publication Number | Publication Date |
---|---|
US7001736B1 true US7001736B1 (en) | 2006-02-21 |
Family
ID=25078098
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/766,975 Expired - Lifetime US6022683A (en) | 1995-04-26 | 1996-12-16 | Methods for assessing the prognosis of a patient with a neurodegenerative disease |
US09/500,162 Expired - Fee Related US7001736B1 (en) | 1995-04-26 | 2000-02-08 | Pharmacogenetic methods for use in the treatment of nervous system diseases |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/766,975 Expired - Lifetime US6022683A (en) | 1995-04-26 | 1996-12-16 | Methods for assessing the prognosis of a patient with a neurodegenerative disease |
Country Status (8)
Country | Link |
---|---|
US (2) | US6022683A (en) |
EP (2) | EP0946753B1 (en) |
JP (4) | JP2001524809A (en) |
AT (1) | ATE269978T1 (en) |
AU (2) | AU5571798A (en) |
CA (2) | CA2275504C (en) |
DE (2) | DE69729654T2 (en) |
WO (2) | WO1998027227A2 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060122270A1 (en) * | 2000-05-01 | 2006-06-08 | Henderson Samuel T | Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism |
US20060252775A1 (en) * | 2005-05-03 | 2006-11-09 | Henderson Samuel T | Methods for reducing levels of disease associated proteins |
US20070135376A1 (en) * | 2005-06-20 | 2007-06-14 | Accera, Inc. | Method to reduce oxidative damage and improve mitochondrial efficiency |
US20070179197A1 (en) * | 2000-05-01 | 2007-08-02 | Accera, Inc. | Compositions and methods for improving or preserving brain function |
US20080009467A1 (en) * | 2000-05-01 | 2008-01-10 | Accera, Inc. | Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism |
US20080287372A1 (en) * | 2000-05-01 | 2008-11-20 | Accera, Inc. | Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment |
US20090171697A1 (en) * | 2005-11-29 | 2009-07-02 | Glauser Tracy A | Optimization and Individualization of Medication Selection and Dosing |
US20100003730A1 (en) * | 2008-07-03 | 2010-01-07 | Accera, Inc. | Enzymatic Synthesis of Acetoacetate Esters and Derivatives |
US20110178032A1 (en) * | 2008-07-03 | 2011-07-21 | Accera, Inc. | Monoglyceride of Acetoacetate and Derivatives for the Treatment of Neurological Disorders |
US20130080182A1 (en) * | 2011-09-26 | 2013-03-28 | Athleticode Inc. | Methods For Using DNA Testing To Screen For Genotypes Relevant To Athleticism, Health And Risk Of Injury |
US8445535B1 (en) | 2000-05-01 | 2013-05-21 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
US8688385B2 (en) | 2003-02-20 | 2014-04-01 | Mayo Foundation For Medical Education And Research | Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype |
US9175345B2 (en) | 2007-07-31 | 2015-11-03 | Accera, Inc. | Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function |
US10658073B2 (en) | 2014-08-15 | 2020-05-19 | QIAGEN Redwood City, Inc. | Methods and systems for interpretation and reporting of sequence-based genetic tests using pooled allele statistics |
US10665328B2 (en) | 2014-06-30 | 2020-05-26 | QIAGEN Redwood City, Inc. | Methods and systems for interpretation and reporting of sequence-based genetic tests |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6022683A (en) * | 1996-12-16 | 2000-02-08 | Nova Molecular Inc. | Methods for assessing the prognosis of a patient with a neurodegenerative disease |
US6441149B1 (en) | 1998-06-15 | 2002-08-27 | Mitokor | Diagnostic method based on quantification of extramitochondrial DNA |
US6218117B1 (en) | 1998-06-15 | 2001-04-17 | Mitokor | Compositions and methods for identifying agents that quantitatively alter detectable extramitochondrial DNA:mitochondrial DNA ratios |
US6489095B2 (en) | 1998-06-15 | 2002-12-03 | Mitokor | Diagnostic method based on quantification of extramitochondrial DNA |
CA2330829C (en) * | 1998-06-16 | 2011-08-02 | Nova Molecular, Inc. | Methods for treating a neurological disease by determining bche genotype |
WO2000020634A1 (en) | 1998-10-01 | 2000-04-13 | Nova Molecular, Inc. | Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele |
EP1179175A2 (en) * | 1999-05-14 | 2002-02-13 | Karolinska Innovations AB | Materials and methods relating to disease diagnosis |
DE00941722T1 (en) * | 1999-06-25 | 2004-04-15 | Genaissance Pharmaceuticals Inc., New Haven | PROCESS FOR MAINTAINING AND USING HAPLOTYPE DATA |
US7058517B1 (en) | 1999-06-25 | 2006-06-06 | Genaissance Pharmaceuticals, Inc. | Methods for obtaining and using haplotype data |
US6960439B2 (en) * | 1999-06-28 | 2005-11-01 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
US6692916B2 (en) * | 1999-06-28 | 2004-02-17 | Source Precision Medicine, Inc. | Systems and methods for characterizing a biological condition or agent using precision gene expression profiles |
US6573049B1 (en) | 1999-07-26 | 2003-06-03 | Nuvelo, Inc. | Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease |
US6896881B1 (en) * | 1999-09-24 | 2005-05-24 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
WO2001069261A2 (en) * | 2000-03-15 | 2001-09-20 | Oxford Glycosciences (Uk) Ltd. | Proteins, genes and their use for diagnosis and treatment of vascular dementia |
US6931326B1 (en) | 2000-06-26 | 2005-08-16 | Genaissance Pharmaceuticals, Inc. | Methods for obtaining and using haplotype data |
ES2296893T3 (en) * | 2001-02-12 | 2008-05-01 | N.V. Organon | USE OF MIRTAZAPINE FOR THE TREATMENT OF SEVERE DEPRESSION IN A HUMAN PATIENT AND CARRIER OF THE APOLIPOPROTEIN E4 GENE. |
US6399310B1 (en) | 2001-02-12 | 2002-06-04 | Akzo Nobel N.V. | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
US20030105082A1 (en) * | 2001-12-03 | 2003-06-05 | Murphy Greer Marechal | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
GB0106051D0 (en) * | 2001-03-12 | 2001-05-02 | Isis Innovation | Diagnostic screens for alzheimer's disease |
US20030104453A1 (en) * | 2001-11-06 | 2003-06-05 | David Pickar | System for pharmacogenetics of adverse drug events |
JP5236856B2 (en) | 2001-11-09 | 2013-07-17 | ライフ テクノロジーズ コーポレーション | Identification, observation and treatment of diseases and identification of biological states using gene expression profiles |
US20030224446A1 (en) * | 2001-12-20 | 2003-12-04 | Harry G. Jean | Method of predicting cytokine response to tissue injury |
US20040267458A1 (en) * | 2001-12-21 | 2004-12-30 | Judson Richard S. | Methods for obtaining and using haplotype data |
WO2003069431A2 (en) * | 2002-02-14 | 2003-08-21 | Medavante, Inc. | System and method for facilitating candidate and subject participation in clinical trial studies |
US7432355B2 (en) * | 2002-08-09 | 2008-10-07 | The J. David Gladstone Institutes | Apolipoprotein E stable folding intermediate and methods of use thereof |
CA2525517C (en) * | 2003-06-19 | 2016-05-31 | Applied Research Systems Ars Holding N.V. | Use of prion conversion modulating agents |
US20050038692A1 (en) * | 2003-08-14 | 2005-02-17 | Kane John Michael | System and method for facilitating centralized candidate selection and monitoring subject participation in clinical trial studies |
ZA200605829B (en) * | 2004-01-16 | 2007-11-28 | Disease Man Services Plc | Disease Management System |
AU2005263578B2 (en) | 2004-07-16 | 2010-09-02 | Proteosys Ag | Muscarinic antagonists with PARP and SIR modulating activity as agents for inflammatory diseases |
US20080126118A1 (en) * | 2006-11-24 | 2008-05-29 | General Electric Company, A New York Corporation | Systems, methods and apparatus for a network application framework system |
TWI362012B (en) * | 2007-07-23 | 2012-04-11 | System of providing hygienic education information and method thereof | |
US20090198504A1 (en) * | 2008-02-05 | 2009-08-06 | Medavante, Inc. | Rater resource allocation systems and methods |
WO2010081825A2 (en) | 2009-01-13 | 2010-07-22 | Proteosys Ag | Pirenzepine as an agent in cancer treatment |
EP2360280A1 (en) * | 2010-02-24 | 2011-08-24 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Genetic marker for the diagnosis of dementia with Lewy bodies |
US20120078521A1 (en) * | 2010-09-27 | 2012-03-29 | General Electric Company | Apparatus, system and methods for assessing drug efficacy using holistic analysis and visualization of pharmacological data |
RU2467680C1 (en) * | 2011-10-04 | 2012-11-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации | Method for prediction of clinical effectiveness in patients with ischemic stroke |
EP3628315A1 (en) | 2018-09-28 | 2020-04-01 | Université de Caen Normandie | Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases |
WO2020091375A2 (en) * | 2018-10-29 | 2020-05-07 | 고려대학교 산학협력단 | Antidepressant recommendation method and system |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994009155A1 (en) | 1992-10-13 | 1994-04-28 | Duke University | Methods of detecting alzheimer's disease |
WO1995016791A1 (en) | 1993-12-15 | 1995-06-22 | Mcgill University | Apolipoprotein e polymorphism and alzheimer's disease |
FR2716894A1 (en) | 1994-03-07 | 1995-09-08 | Pasteur Institut | Genetic markers used together for the diagnosis of Alzheimer's disease, method and diagnostic kit. |
WO1995029257A2 (en) | 1994-04-27 | 1995-11-02 | Mcgill University | Apolipoprotein e polymorphism and treatment of alzheimer's disease |
WO1996002670A1 (en) | 1994-07-20 | 1996-02-01 | Smithkline Beecham Plc | Methods of prognosing the course and degree of dementia in patients with beta-amyloid-related diseases |
WO1996003656A1 (en) | 1994-06-27 | 1996-02-08 | Smithkline Beecham Plc | Novel method of prognosing chronic neurodegenerative pathology following a head injury |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6022683A (en) * | 1996-12-16 | 2000-02-08 | Nova Molecular Inc. | Methods for assessing the prognosis of a patient with a neurodegenerative disease |
-
1996
- 1996-12-16 US US08/766,975 patent/US6022683A/en not_active Expired - Lifetime
-
1997
- 1997-12-16 AU AU55717/98A patent/AU5571798A/en not_active Withdrawn
- 1997-12-16 JP JP52750798A patent/JP2001524809A/en not_active Withdrawn
- 1997-12-16 EP EP97953011A patent/EP0946753B1/en not_active Expired - Lifetime
- 1997-12-16 AU AU56757/98A patent/AU745073B2/en not_active Ceased
- 1997-12-16 CA CA002275504A patent/CA2275504C/en not_active Expired - Fee Related
- 1997-12-16 DE DE69729654T patent/DE69729654T2/en not_active Expired - Lifetime
- 1997-12-16 EP EP97952129A patent/EP0948647B1/en not_active Expired - Lifetime
- 1997-12-16 AT AT97952129T patent/ATE269978T1/en not_active IP Right Cessation
- 1997-12-16 WO PCT/IB1997/001648 patent/WO1998027227A2/en active IP Right Grant
- 1997-12-16 WO PCT/IB1997/001641 patent/WO1998027226A2/en active IP Right Grant
- 1997-12-16 CA CA2275404A patent/CA2275404C/en not_active Expired - Fee Related
- 1997-12-16 DE DE69729473T patent/DE69729473T2/en not_active Expired - Lifetime
-
2000
- 2000-02-08 US US09/500,162 patent/US7001736B1/en not_active Expired - Fee Related
-
2009
- 2009-05-07 JP JP2009113073A patent/JP5202429B2/en not_active Expired - Fee Related
-
2012
- 2012-05-23 JP JP2012117411A patent/JP2012152229A/en active Pending
- 2012-12-17 JP JP2012274378A patent/JP2013059347A/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994009155A1 (en) | 1992-10-13 | 1994-04-28 | Duke University | Methods of detecting alzheimer's disease |
US5508167A (en) | 1992-10-13 | 1996-04-16 | Duke University | Methods of screening for Alzheimer's disease |
WO1995016791A1 (en) | 1993-12-15 | 1995-06-22 | Mcgill University | Apolipoprotein e polymorphism and alzheimer's disease |
FR2716894A1 (en) | 1994-03-07 | 1995-09-08 | Pasteur Institut | Genetic markers used together for the diagnosis of Alzheimer's disease, method and diagnostic kit. |
WO1995029257A2 (en) | 1994-04-27 | 1995-11-02 | Mcgill University | Apolipoprotein e polymorphism and treatment of alzheimer's disease |
US5935781A (en) * | 1994-04-27 | 1999-08-10 | Mcgill University | Apolipoprotein E polymorphism and treatment of Alzheimer's disease |
WO1996003656A1 (en) | 1994-06-27 | 1996-02-08 | Smithkline Beecham Plc | Novel method of prognosing chronic neurodegenerative pathology following a head injury |
WO1996002670A1 (en) | 1994-07-20 | 1996-02-01 | Smithkline Beecham Plc | Methods of prognosing the course and degree of dementia in patients with beta-amyloid-related diseases |
Non-Patent Citations (60)
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060122270A1 (en) * | 2000-05-01 | 2006-06-08 | Henderson Samuel T | Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism |
US8426468B2 (en) | 2000-05-01 | 2013-04-23 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer'S disease and other diseases resulting from reduced neuronal metabolism |
US8445535B1 (en) | 2000-05-01 | 2013-05-21 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
US20070179197A1 (en) * | 2000-05-01 | 2007-08-02 | Accera, Inc. | Compositions and methods for improving or preserving brain function |
US20080009467A1 (en) * | 2000-05-01 | 2008-01-10 | Accera, Inc. | Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism |
US20080287372A1 (en) * | 2000-05-01 | 2008-11-20 | Accera, Inc. | Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment |
US8124589B2 (en) | 2000-05-01 | 2012-02-28 | Accera, Inc. | Use of ketogenic compounds for treatment of age-associated memory impairment |
US10111849B2 (en) | 2000-05-01 | 2018-10-30 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
US9603823B2 (en) | 2000-05-01 | 2017-03-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
US8688385B2 (en) | 2003-02-20 | 2014-04-01 | Mayo Foundation For Medical Education And Research | Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype |
US20100034745A1 (en) * | 2005-05-03 | 2010-02-11 | Neuera Pharmaceuticals, Inc. | Method for Reducing Levels of Disease Associated Proteins |
US20060252775A1 (en) * | 2005-05-03 | 2006-11-09 | Henderson Samuel T | Methods for reducing levels of disease associated proteins |
US20100041751A1 (en) * | 2005-06-20 | 2010-02-18 | Accera, Inc. | Method to Reduce Oxidative Damage and Improve Mitochondrial Efficiency |
US20070135376A1 (en) * | 2005-06-20 | 2007-06-14 | Accera, Inc. | Method to reduce oxidative damage and improve mitochondrial efficiency |
US20090171697A1 (en) * | 2005-11-29 | 2009-07-02 | Glauser Tracy A | Optimization and Individualization of Medication Selection and Dosing |
US8589175B2 (en) | 2005-11-29 | 2013-11-19 | Children's Hospital Medical Center | Optimization and individualization of medication selection and dosing |
US8748400B2 (en) | 2006-04-03 | 2014-06-10 | Accera, Inc. | Use of ketogenic compounds for treatment of age-associated memory impairment |
US9175345B2 (en) | 2007-07-31 | 2015-11-03 | Accera, Inc. | Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function |
US10105338B2 (en) | 2007-07-31 | 2018-10-23 | Accera, Inc. | Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function |
US8105809B2 (en) | 2008-07-03 | 2012-01-31 | Accera, Inc. | Enzymatic synthesis of acetoacetate esters and derivatives |
US9125881B2 (en) | 2008-07-03 | 2015-09-08 | Accera, Inc. | Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders |
US20110178032A1 (en) * | 2008-07-03 | 2011-07-21 | Accera, Inc. | Monoglyceride of Acetoacetate and Derivatives for the Treatment of Neurological Disorders |
US20100003730A1 (en) * | 2008-07-03 | 2010-01-07 | Accera, Inc. | Enzymatic Synthesis of Acetoacetate Esters and Derivatives |
US20130080182A1 (en) * | 2011-09-26 | 2013-03-28 | Athleticode Inc. | Methods For Using DNA Testing To Screen For Genotypes Relevant To Athleticism, Health And Risk Of Injury |
US10665328B2 (en) | 2014-06-30 | 2020-05-26 | QIAGEN Redwood City, Inc. | Methods and systems for interpretation and reporting of sequence-based genetic tests |
US10658073B2 (en) | 2014-08-15 | 2020-05-19 | QIAGEN Redwood City, Inc. | Methods and systems for interpretation and reporting of sequence-based genetic tests using pooled allele statistics |
Also Published As
Publication number | Publication date |
---|---|
AU5571798A (en) | 1998-07-15 |
WO1998027226A2 (en) | 1998-06-25 |
EP0948647B1 (en) | 2004-06-23 |
JP2001524809A (en) | 2001-12-04 |
EP0948647A1 (en) | 1999-10-13 |
US6022683A (en) | 2000-02-08 |
JP5202429B2 (en) | 2013-06-05 |
JP2012152229A (en) | 2012-08-16 |
EP0946753A2 (en) | 1999-10-06 |
WO1998027227A3 (en) | 1998-08-27 |
AU745073B2 (en) | 2002-03-14 |
DE69729654T2 (en) | 2005-07-21 |
CA2275504A1 (en) | 1998-06-25 |
CA2275404A1 (en) | 1998-06-25 |
ATE269978T1 (en) | 2004-07-15 |
EP0946753B1 (en) | 2004-06-09 |
JP2009213482A (en) | 2009-09-24 |
JP2013059347A (en) | 2013-04-04 |
DE69729654D1 (en) | 2004-07-29 |
AU5675798A (en) | 1998-07-15 |
WO1998027226A3 (en) | 1998-08-20 |
WO1998027227A2 (en) | 1998-06-25 |
DE69729473T2 (en) | 2005-06-09 |
CA2275404C (en) | 2011-02-08 |
CA2275504C (en) | 2009-09-22 |
DE69729473D1 (en) | 2004-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7001736B1 (en) | Pharmacogenetic methods for use in the treatment of nervous system diseases | |
EP0804615B1 (en) | Apolipoprotein e polymorphism and treatment of alzheimer's disease | |
Emrani et al. | APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer’s disease: a systematic review | |
Galfalvy et al. | A genome‐wide association study of suicidal behavior | |
Del Bo et al. | Vascular endothelial growth factor gene variability is associated with increased risk for AD | |
Lehtovirta et al. | Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism | |
Allen et al. | Late-onset Alzheimer disease risk variants mark brain regulatory loci | |
Zetterberg et al. | Association of complement factor H Y402H gene polymorphism with Alzheimer's disease | |
Xiao et al. | Association studies of several cholesterol-related genes (ABCA1, CETP and LIPC) with serum lipids and risk of Alzheimer’s disease | |
Sawa et al. | Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model | |
Lim et al. | BDNF VAL66MET polymorphism and memory decline across the spectrum of Alzheimer's disease | |
Ghaffar et al. | APOE ϵ4 and cognitive dysfunction in multiple sclerosis: a review | |
US7049078B2 (en) | Apolipoprotein E polymorphism and treatment of alzheimer's disease | |
Smach et al. | Polymorphism in apoA1 influences high-density lipoprotein cholesterol levels but is not a major risk factor of alzheimer’s disease | |
Chou et al. | Angiotensin‐converting enzyme insertion/deletion polymorphism and the longitudinal progression of Alzheimer's disease | |
Li et al. | CYP46A1 and the APOEε4 allele polymorphisms correlate with the risk of Alzheimer’s disease | |
Blain et al. | A polymorphism in lipoprotein lipase affects the severity of Alzheimer's disease pathophysiology | |
Pierzchlińska et al. | The impact of Apolipoprotein E alleles on cognitive performance in patients with Parkinson's disease | |
Nakayama et al. | Apolipoprotein E phenotypes in healthy normal controls and demented subjects with Alzheimer’s disease and vascular dementia in Mie Prefecture of Japan | |
Chen et al. | PPP2R2B CAG repeat length in the Han Chinese in Taiwan: association analyses in neurological and psychiatric disorders and potential functional implications | |
Ramadan et al. | Association analysis of ApoE gene polymorphisms among Egyptian patients with Alzheimer's disease | |
Helisalmi et al. | The leucine (7)-to-proline (7) polymorphism in the signal peptide of neuropeptide Y is not associated with Alzheimer's disease or the link apolipoprotein E | |
AU733237B2 (en) | Use of Apolipoprotein polymorphism E in the treatment of Alzheimer's disease | |
Bhattarai et al. | Rare genetic variation in Fibronectin 1 (FN1) protects against APOEe4 in Alzheimer's disease | |
Eklind | The effect of the APOE genotype on Alzheimer´ s pathology in pathological ageing and Alzheimer´ s disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NOVA MOLECULAR INC., CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:POIRIER, JUDES;REEL/FRAME:011926/0825 Effective date: 19970729 Owner name: VARIAGENICS, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MILLER, DANIEL S.;REEL/FRAME:011926/0707 Effective date: 20010406 |
|
AS | Assignment |
Owner name: NUVELO, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VARIAGENICS, INC.;HYSEQ, INC.;REEL/FRAME:017240/0652 Effective date: 20030131 Owner name: MCGILL UNIVERSITY, CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NUVELO, INC.;REEL/FRAME:017251/0150 Effective date: 20050507 |
|
AS | Assignment |
Owner name: POIRIER, JUDES, CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MCGILL UNIVERSITY;REEL/FRAME:017240/0778 Effective date: 20041028 |
|
FEPP | Fee payment procedure |
Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: HYSEQ, INC. UNDER THE NAME OF NUVELO, INC., CALIFO Free format text: MERGER;ASSIGNOR:VARIAGENICS, INC.;REEL/FRAME:022259/0806 Effective date: 20030131 Owner name: POIRIER, JUDES, CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MCGILL UNIVERSITY;REEL/FRAME:022259/0813 Effective date: 20041028 Owner name: VARIAGENICS, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVA MOLECULAR INC.;REEL/FRAME:022259/0792 Effective date: 20001214 Owner name: TECHNO-SYNAPSE INC., CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:POIRIER, JUDES;REEL/FRAME:022259/0826 Effective date: 20050115 Owner name: SPECTRAL NEUROSCIENCE INC., CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TECHNO-SYNAPSE INC.;REEL/FRAME:022259/0851 Effective date: 20070628 Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICALS LTD., BERMU Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SPECTRAL NEUROSCIENCE INC.;REEL/FRAME:022259/0859 Effective date: 20070628 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.) |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.) |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20180221 |